Abstract
Pituitary gland tumors represent approximately 10–15% of all brain tumors and the most common neoplasms of the sellar region. Among them, pituitary adenomas are the widespread accounting for more than 80%. Recently, the fourth edition of the World Health Organization (WHO) 2017 classified pituitary tumors focusing on histopathologic and molecular genetics features and introduced new entities like pituitary blastoma. Most of pituitary gland neoplasms occur sporadically, whereas 5% are related to familial syndromes. They present with several clinical manifestations including signs and symptoms related to excessive hormone secretion by the tumor, signs of hormone deficits by the normal pituitary gland and others commonly secondary to mass effects, and compression of nearby structures such as the optic chiasm; headache and visual disturbance are the most frequent mass effect symptoms. Some tumors, however, are detected as an incidental finding on magnetic resonance imaging (MRI) or computed tomography (CT) scans performed for some other reasons. A correct evaluation involves the assessment of hypothalamic–pituitary hormonal function and an ophthalmological examination once a pituitary lesion is encountered. Surgery, more specifically transsphenoidal approach, represents the primary treatment chosen for the majority of pituitary tumors (except for prolactinomas where medical treatment is indicated) allowing for pathologic analysis and complete or partial tumor removal. On the contrary, to date, craniotomy is rarely performed. Sometimes, due to the proximity of critical structures and to tumor’s location and characteristics, a successful surgical procedure may often not be achievable due to the high risks related to the procedure itself. Therefore, the treatment of pituitary tumors commonly requires a multimodal approach, including surgery, radiosurgery, radiation therapy, and medical therapy. Aggressive pituitary tumors or carcinomas are associated with poor prognosis due to limited therapeutic options. Furthermore, they tend to recur quickly after initial surgical treatment or present metastasis, may be unresponsive to therapy, and are difficult to manage. In this chapter, we provide an overview of the most common pituitary gland tumors focusing on epidemiology, new pathological features, diagnosis, available treatment, and prognosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akyoldas G, Hergunsel OB, Ozdemir IE, Sengoz M, Peker S (2019) Gamma knife radiosurgery for pituitary spindle cell oncocytomas. Clin Neurol Neurosurg 187:105560. https://doi.org/10.1016/j.clineuro.2019.105560
Al-Shraim M, Asa SL (2006) The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol 111:1–7. https://doi.org/10.1007/s00401-005-1093-6
Albano L, Losa M, Flickinger J, Mortini P, Minniti G (2020) Radiotherapy of parasellar tumours. Neuroendocrinology 110:848-858. https://doi.org/10.1159/000506902
Albano L et al (2019) Safety and efficacy of multisession gamma knife radiosurgery for residual or recurrent pituitary adenomas. Endocrine 64:639–647. https://doi.org/10.1007/s12020-019-01876-2
Ammirati M, Wei L, Ciric I (2013) Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 84:843–849. https://doi.org/10.1136/jnnp-2012-303194
Arafah BM, Nasrallah MP (2001) Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 8:287–305. https://doi.org/10.1677/erc.0.0080287
Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85:1789–1793. https://doi.org/10.1210/jcem.85.5.6611
Barzaghi LR, Medone M, Losa M, Bianchi S, Giovanelli M, Mortini P (2012) Prognostic factors of visual field improvement after trans-sphenoidal approach for pituitary macroadenomas: review of the literature and analysis by quantitative method. Neurosurg Rev 35:369–378; discussion 378–369. https://doi.org/10.1007/s10143-011-0365-y
Bonneville JF (2016) Magnetic resonance imaging of pituitary tumors. Front Horm Res 45:97–120. https://doi.org/10.1159/000442327
Borg A, Jaunmuktane Z, Dorward N (2020) Tumors of the neurohypophysis: one unit's experience and literature review. World Neurosurg 134:e968–e978. https://doi.org/10.1016/j.wneu.2019.11.043
Buchfelder M, Schlaffer S (2014) Imaging of pituitary pathology Handb Clin Neurol 124:151–166. https://doi.org/10.1016/B978-0-444-59602-4.00011-3
Chatzellis E, Alexandraki KI, Androulakis, II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101:87–104. https://doi.org/10.1159/000371806
Colao A, Ochoa AS, Auriemma RS, Faggiano A, Pivonello R, Lombardi G (2010) Pituitary carcinomas. Front Horm Res 38:94–108. https://doi.org/10.1159/000318499
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege. Belgium J Clin Endocrinol Metab 91:4769–4775. https://doi.org/10.1210/jc.2006-1668
Faltermeier CM, Magill ST, Blevins LS Jr, Aghi MK (2019) Molecular biology of pituitary adenomas. Neurosurg Clin N Am 30:391–400. https://doi.org/10.1016/j.nec.2019.05.001
Famini P, Maya MM, Melmed S (2011) Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 96:1633–1641. https://doi.org/10.1210/jc.2011-0168
Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.x
Gagliardi F, Spina A, Barzaghi LR, Bailo M, Losa M, Terreni MR, Mortini P (2016) Suprasellar granular cell tumor of the neurohypophysis: surgical outcome of a very rare tumor. Pituitary 19:277–285. https://doi.org/10.1007/s11102-016-0704-7
Giantini Larsen AM et al (2018) Spindle cell oncocytoma of the pituitary gland. J Neurosurg 131:517–525. https://doi.org/10.3171/2018.4.JNS18211
Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534. https://doi.org/10.1210/er.2005-9998
Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH (1994) Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120:817–820. https://doi.org/10.7326/0003-4819-120-10-199405150-00001
Hardy J, Vezina JL (1976) Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol 15:261-273
Ilie MD, Lasolle H, Raverot G (2019) Emerging and novel treatments for pituitary tumors. J Clin Med 8. https://doi.org/10.3390/jcm8081107
Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–617; discussion 617–618. https://doi.org/10.1227/00006123-199310000-00008
Langlois F, Chu J, Fleseriu M (2018) Pituitary-directed therapies for cushing's disease. Front Endocrinol (Lausanne) 9:164. https://doi.org/10.3389/fendo.2018.00164
Losa M et al (2016) Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neurooncol 126:519–525. https://doi.org/10.1007/s11060-015-1991-y
Losa M, Spatola G, Albano L, Gandolfi A, Del Vecchio A, Bolognesi A, Mortini P (2017) Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas. Endocrine 56:595–602. https://doi.org/10.1007/s12020-016-1081-8
Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7:257–266. https://doi.org/10.1038/nrendo.2011.40
Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28:228–243. https://doi.org/10.1007/s12022-017-9498-z
Minniti G, Clarke E, Scaringi C, Enrici RM (2016) Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother 21:370–378. https://doi.org/10.1016/j.rpor.2014.09.004
Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317:516–524. https://doi.org/10.1001/jama.2016.19699
Mortini P, Albano L, Barzaghi LR, Spina A, Losa M (2021) The open sella technique for surgical treatment of pituitary macroadenomas: safety and efficacy in a large clinical series. Br J Neurosurg 1–8. https://doi.org/10.1080/02688697.2021.1950629
Mortini P, Barzaghi LR, Albano L, Panni P, Losa M (2018) Microsurgical therapy of pituitary adenomas. Endocrine 59:72–81. https://doi.org/10.1007/s12020-017-1458-3
Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M (2007) Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 60:993–1002; discussion 1003–1004. https://doi.org/10.1227/01.NEU.0000255459.14764.BA
Neou M et al (2020) Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37(123–134):e125. https://doi.org/10.1016/j.ccell.2019.11.002
Raverot G, Jouanneau E, Trouillas J (2014) Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol 170:R121-132. https://doi.org/10.1530/EJE-13-1031
Robertson JC, Jorcyk CL, Oxford JT (2018) DICER1 syndrome: DICER1 Mutations in Rare Cancers. Cancers (Basel) 10. https://doi.org/10.3390/cancers10050143
Sali A, Epari S, Tampi C, Goel A (2017) Spindle cell oncocytoma of adenohypophysis: review of literature and report of another recurrent case. Neuropathology 37:535–543. https://doi.org/10.1111/neup.12393
Santos-Pinheiro F et al (2019) Treatment and long-term outcomes in pituitary carcinoma: a cohort study. Eur J Endocrinol 181:397–407. https://doi.org/10.1530/EJE-18-0795
Secci F, Merciadri P, Rossi DC, D'Andrea A, Zona G (2012) Pituicytomas: radiological findings, clinical behavior and surgical management. Acta Neurochir (Wien) 154:649–657; discussion 657. https://doi.org/10.1007/s00701-011-1235-7
Wilson CB (1984) A decade of pituitary microsurgery. Herbert Olivecrona Lect J Neurosurg 61:814–833. https://doi.org/10.3171/jns.1984.61.5.0814
Zatelli MC et al (2010) Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 95:968–976. https://doi.org/10.1210/jc.2009-1641
Zhang X, Fei Z, Zhang J, Fu L, Zhang Z, Liu W, Chen Y (1999) Management of nonfunctioning pituitary adenomas with suprasellar extensions by transsphenoidal microsurgery. Surg Neurol 52:380–385. https://doi.org/10.1016/s0090-3019(99)00120-2
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Albano, L., Losa, M., Barzaghi, L.R., Mortini, P. (2023). Benign and Malignant Tumors of the Pituitary Gland. In: Rezaei, N., Hanaei, S. (eds) Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2. Advances in Experimental Medicine and Biology, vol 1405. Springer, Cham. https://doi.org/10.1007/978-3-031-23705-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-031-23705-8_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-23704-1
Online ISBN: 978-3-031-23705-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)